Obesity may compromise GnRH antagonist efficacy through altered ovarian responsiveness—obese patients often require higher gonadotropin doses to achieve comparable oocyte yields (32) and exhibit 18%–22% lower viable embryo rates vs. normal-BMI counterparts (33). This evidence concerns the gene GNRH1 and obesity disorder.